 Non-invasive methods to monitor pancreatic beta-cell loss associated with type-1 diabetes mellitus T1DM could improve early diagnosis, provide tools to measure responsiveness to new therapies, and evaluate the efficiency of pancreatic transplantation and graft survival. 